Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;52:573-580
Published online before print August 4, 2008, doi: 10.1161/HYPERTENSIONAHA.108.112292
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
52/3/573    most recent
HYPERTENSIONAHA.108.112292v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, E.
Right arrow Articles by Kim-Mitsuyama, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, E.
Right arrow Articles by Kim-Mitsuyama, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Obesity
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Type 2 diabetes
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2008;52:573.)
© 2008 American Heart Association, Inc.


Original Articles

Olmesartan Prevents Cardiovascular Injury and Hepatic Steatosis in Obesity and Diabetes, Accompanied by Apoptosis Signal Regulating Kinase-1 Inhibition

Eiichiro Yamamoto; Yi-Fei Dong; Keiichiro Kataoka; Takuro Yamashita; Yoshiko Tokutomi; Shinji Matsuba; Hidenori Ichijo; Hisao Ogawa; Shokei Kim-Mitsuyama

From the Departments of Pharmacology and Molecular Therapeutics (E.Y., Y-F.D., K.K., T.Y., Y.T., S.M., S.K-M.) and Cardiovascular Medicine (H.O.), Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; and the Laboratory of Cell Signaling (H.I.), Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

Correspondence to Shokei Kim-Mitsuyama, Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjyo, Kumamoto 860-8556, Japan. E-mail kimmitsu{at}gpo.kumamoto-u.ac.jp

Dietary obesity is associated with type 2 diabetes and cardiovascular diseases, although the underlying mechanism is unknown. This study was undertaken to elucidate the role of angiotensin II and apoptosis signal regulating kinase-1 (ASK1) in obesity/diabetes-associated cardiovascular complications and hepatic steatosis. Mice fed a high-fat diet were treated with olmesartan, an angiotensin II type 1 receptor blocker, to elucidate the role of angiotensin II in diabetic mice. Treatment of mice fed a high-fat diet with olmesartan markedly suppressed cardiac inflammation and fibrosis, as well as vascular endothelial dysfunction and remodeling, induced by obesity/diabetes. Moreover, olmesartan suppressed the disruption of the vascular endothelial NO synthase dimer in diabetic mice. Olmesartan also significantly prevented hepatic steatosis and fibrosis in diabetic mice. These beneficial effects of olmesartan on diabetic mice were associated with the attenuation of ASK1 activation in these mice. ASK1-deficient mice and wild-type mice were compared, regarding the effects of a high-fat diet. A comparison between ASK1-deficient and wild-type mice showed that ASK1 deficiency attenuated cardiac inflammation and fibrosis, as well as vascular endothelial dysfunction and remodeling induced by obesity/diabetes. The amelioration of vascular endothelial impairment by ASK1 deficiency was attributed to the prevention of endothelial NO synthase dimer disruption. ASK1 deficiency also significantly lessened hepatic steatosis in diabetic mice. In conclusion, our work provided the evidence that ASK1 is significantly activated in diet-induced diabetic mice and contributes to cardiovascular diseases and hepatic steatosis in diabetic mice. Moreover, the beneficial effects of angiotensin II inhibition on dietary diabetic mice seem to be mediated by the inhibition of ASK1 activation.


Key Words: diabetes • obesity • angiotensin • ASK1 • reactive oxygen species • vascular endothelial function • cardiac injury




This article has been cited by other articles:


Home page
HypertensionHome page
E. Yamamoto, K. Kataoka, Y.-F. Dong, T. Nakamura, M. Fukuda, Y. Tokutomi, S. Matsuba, H. Nako, N. Nakagata, T. Kaneko, et al.
Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase-Deficient Mice
Hypertension, September 1, 2009; 54(3): 633 - 638.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Bluher, N. Bashan, I. Shai, I. Harman-Boehm, T. Tarnovscki, E. Avinaoch, M. Stumvoll, A. Dietrich, N. Kloting, and A. Rudich
Activated Ask1-MKK4-p38MAPK/JNK Stress Signaling Pathway in Human Omental Fat Tissue May Link Macrophage Infiltration to Whole-Body Insulin Sensitivity
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2507 - 2515.
[Abstract] [Full Text] [PDF]